S. Impera

发表

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

A. Stamatoullas, M. Voso, R. Latagliata, 2017, The Lancet. Haematology.

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

R. Latagliata, I. Vincelli, M. Breccia, 2011, Haematologica.

Quality of Life in Elderly Patients with Acute Myeloid Leukemia.

R. Latagliata, I. Vincelli, M. Breccia, 2004 .

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)

P. Mazza, V. Pavone, P. Guglielmelli, 2021, Leukemia & lymphoma.

Quality of life and physicians' perception in myelodysplastic syndromes.

A. Levis, D. Cilloni, C. Finelli, 2012, American journal of blood research.

JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

R. Latagliata, R. Gale, G. Barosi, 2016, Leukemia.

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib

E. Tirrò, P. Vigneri, S. Russo, 2019, International journal of molecular sciences.

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)

P. Mazza, V. Pavone, P. Guglielmelli, 2021, Leukemia & lymphoma.

Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life

R. Latagliata, A. Risitano, I. Vincelli, 2010, Leukemia & lymphoma.

P-310 Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial

M. Voso, R. Latagliata, F. Morabito, 2013 .

Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial

P. Bartolomeo, A. Stamatoullas, R. Latagliata, 2015 .

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

M. Voso, R. Latagliata, P. Fenaux, 2019, Blood.

In vitro sensitivity of B-CLL cells to fludarabine and interferons.

F. Di Raimondo, G. Milone, S. Impera, 1995, Leukemia & lymphoma.

“On‐demand” treatment with Thrombopoietin mimetics as “bridge to recovery” from chemotherapy in chronic immune thrombocytopenia patients with cancer. A single centre experience in nine patients

U. Consoli, S. Impera, A. Todaro, 2018, British journal of haematology.

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

E. Tirrò, P. Vigneri, C. Musolino, 2019, Front. Oncol..

High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Martin C. Müller, S. Molica, P. Vigneri, 2017, Clinical Cancer Research.

A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line

M. Baccarani, G. Rosti, G. Martinelli, 2017, American journal of hematology.

High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib

Martin C. Müller, C. Musolino, S. Forte, 2013 .

CD34 expression in adult acute lymphoblastic leukemia.

F. Stagno, S. Impera, R. Cacciola, 1995, Leukemia & lymphoma.

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

G. Specchia, M. Gobbi, R. Fanin, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.